Business Wire

NY-ESTÉE-LAUDER

2.9.2021 21:07:08 CEST | Business Wire | Press release

Share
The Estée Lauder Companies and Estée Lauder Brand Announce Partnership With Amanda Gorman

Today, The Estée Lauder Companies Inc. (NYSE:EL) and the Estée Lauder brand announced a three-year partnership with Amanda Gorman, activist, award-winning writer, and the youngest inaugural poet in U.S. history. This is the first such multi-year partnership for Amanda and the first integrated partnership by The Estée Lauder Companies and the Estée Lauder brand to acknowledge and celebrate a new generation of leaders inspiring change.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005711/en/

As part of this unprecedented partnership, The Estée Lauder Companies will contribute US$3M over three years to support WRITING CHANGE, a special initiative to advance literacy as a pathway to equality, access, and social change. In addition, Amanda will bring her voice of change to the Estée Lauder brand through campaigns debuting in Spring 2022.

“Our company was founded by an extraordinary woman, Estée Lauder, who paved the way for women everywhere to believe anything is possible. Our first of its kind partnership with Amanda was created under these very same trailblazing ideals,” said Jane Hertzmark Hudis, Executive Group President, The Estée Lauder Companies. “Amanda’s powerful presence and inspirational voice brings hope and confidence to the next generation of leaders. Together, we will create real and meaningful impact through literacy, voice, and self-expression.”

The Estée Lauder Companies and Amanda are united in supporting causes for equality and social impact. The WRITING CHANGE initiative is strongly aligned with the goals of The Estée Lauder Companies and The Estée Lauder Companies Charitable Foundation, which focuses on the well-being of diverse global communities, emphasizing women and girls, supported by the pillars of health, education, and the environment.

“I am honored to partner with The Estée Lauder Companies to activate change through literacy, and to represent a brand founded by such an inspiring and daring woman,” said Amanda Gorman. “Mrs. Estée Lauder shattered glass ceilings as a leader in business 75 years ago. Embracing this spirit, I am delighted that our partnership will help inspire women, girls, and all people around the world to do great things, to disrupt, to be confident, and to be future leaders in whatever path they take.”

“Amanda embodies a new generation and demonstrates the importance and influence of voice,” said Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies. “As a company, we are committed to nurturing the leaders and talent of the future, empowering them to use their voices—and to use them loudly. We are thrilled to partner with Amanda as we embark on this collective journey to strengthen our commitment to girls’ education, helping provide the skills needed to be heard around the globe.”

This year, The Estée Lauder Companies and the Estée Lauder brand celebrate 75 years in business, and today the company is the world’s leader in prestige beauty, supported by a global workforce that is 84% female. In March 2021, the company published its commitments to gender equality and women’s advancement , with initiatives committed to levelling the playing field for all genders inside and outside the company.

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

About Estée Lauder
Estée Lauder is the flagship brand of The Estée Lauder Companies Inc. Founded by Estée Lauder, one of the world’s first female entrepreneurs, the brand today continues her legacy of creating innovative, sophisticated, high-performance skincare and makeup products and iconic fragrances – all infused with a deep understanding of women’s needs and desires. Today, Estée Lauder engages with women in over 150 countries and territories around the world and at dozens of touch points – from in-store to digital. And each of these relationships consistently reflects Estée’s powerful and authentic woman-to-woman point of view.

About The Estée Lauder Companies Charitable Foundation (ELCCF)
Fueled by our company values and employees’ passions, the mission of ELCCF is to improve the well-being of our diverse global communities, with an emphasis on women and girls. ELCCF focuses our efforts on three pillars: health, education and the environment and make annual grants to organizations in the United States and around the world that align with these pillars.

About Amanda Gorman
Amanda Gorman is the youngest inaugural poet in U.S. history. She is a committed advocate for the environment, racial equality, and gender justice. Amanda’s activism and poetry have been featured on the Today Show , PBS Kids, and CBS This Morning , and in the New York Times , Vogue , and Essence . After graduating cum laude from Harvard University, she now lives in her hometown of Los Angeles. In 2017, Amanda Gorman was appointed the first-ever National Youth Poet Laureate by Urban Word – a program that supports Youth Poets Laureate in more than 60 cities, regions and states nationally. Gorman’s performance of her poem “The Hill We Climb” at the 2021 Presidential Inauguration received critical acclaim and international attention. The special edition of her inaugural poem, “The Hill We Climb,” was published in March 2021 and debuted at #1 on the New York Times, USA Today and Wall Street Journal bestsellers list. Amanda appeared on the cover of TIME magazine in February 2021 and was the first poet to grace the cover of Vogue in their May 2021 issue. She was Porter Magazine's July 2021cover star and received The Artist Impact Award at the 2021 Backstage at the Geffen Awards. Her debut picture book, Change Sings , will be published in September 2021, and her poetry collection, Call Us What We Carry, will release in December 2021. Please visit theamandagorman.com .

Follow @esteelauder on Instagram , Facebook , Twitter , YouTube , and TikTok
Follow @esteelaudercompanies on Instagram , Facebook , and Twitter
Follow @amandascgorman on Instagram

ELC-C
ELC-B

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye